AngioDynamics Announces Market Launch of SpeedLyser Thrombolytic Catheter.Business Editors/Health/Medical Writers QUEENSBURY, N.Y.--(BUSINESS WIRE)--April 13, 2004 AngioDynamics, Inc., a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of E-Z-EM, Inc. (AMEX AMEX See: American Stock Exchange :EZM), announced today the worldwide market launch of the SpeedLyser(TM) Thrombolytic thrombolytic /throm·bo·lyt·ic/ (throm?bo-lit´ik) dissolving or splitting up a thrombus, or an agent that so acts. thrombolytic 1. dissolving or splitting up a thrombus. 2. an agent that dissolves or splits up a thrombus. catheter -- a catheter kit intended for the administration of thrombolytic agents into the peripheral vasculature vasculature /vas·cu·la·ture/ (vas´ku-lah-chur) 1. circulatory system. 2. any part of the circulatory system. vas·cu·la·ture n. . Unlike catheters constructed with side holes, the SpeedLyser(TM) thrombolytic catheter has slits to help evenly distribute the thrombolytic drug to the blockage. This new product also features a coaxial system -- an innovative dual catheter combination of a 3F inner catheter within a 5F outer catheter -- that simplifies access and drug delivery across the entire blocked graft. It also allows a physician to treat a blockage immediately after dissolving the blood clot by providing access for balloon angioplasty through the 5F catheter -- an advantage that helps to minimize overall treatment time and patient discomfort. The SpeedLyser(TM) catheter will be offered in lengths of 10, 15, and 20cm, giving the physician greater flexibility in treating blockages of varying sizes and locations. Commenting on the announcement, Robert M. Rossell, Vice President of Marketing for AngioDynamics, said, "The SpeedLyser(TM) utilizes our patented slit technology for applications in thrombolytic therapy. The product was developed in conjunction with leading Interventional Radiologists and will offer physicians a simplified way to maintain access in dialysis patients." For additional information on the SpeedLyser(TM) Thrombolytic catheter, please contact Al Concemi at 1-800-772-6446, ext. 385, Email aconcemi@angiodynamics.com or visit the AngioDynamics web site at www.angiodynamics.com. About AngioDynamics AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. . AngioDynamics designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat PVD PVD abbr. peripheral vascular disease PVD Peripheral vascular disease, see there and other non-coronary diseases. About E-Z-EM E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. The Company has developed the only CT injector on the market that can help detect contrast extravasation extravasation /ex·trav·a·sa·tion/ (ek-strav?ah-za´shun) 1. a discharge or escape, as of blood, from a vessel into the tissues; blood or other substance so discharged. 2. the process of being extravasated. , the EmpowerCT(R) with patented EDA (1) (Electronic Design Automation) Using the computer to design, lay out, verify and simulate the performance of electronic circuits on a chip or printed circuit board. (TM) technology; it also offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a carbon dioxide colon insufflation insufflation /in·suf·fla·tion/ (-sah-fla´shun) 1. the act of blowing a powder, vapor, or gas into a body cavity. 2. finely powdered or liquid drugs carried into the respiratory passages by such devices as aerosols. system. The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans", "believes", "seeks", "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, market acceptance of The Speedlyser(TM) Thrombolytic Catheter, future actions by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations, competition, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended February 28,2004, as well as its Annual Report on Form 10-K for the year ended May 31, 2003, may affect the actual results achieved by the Company. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion